Home » CELTIC PHARMA COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO XERECEPT
CELTIC PHARMA COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO XERECEPT
Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") and Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") today announce the close of Celtic Pharma's acquisition of exclusive worldwide rights to XERECEPT(R), a Phase III clinical compound for the treatment for Peritumoral Brain Edema. The closing of the transaction, which was originally announced on September 20, 2005, follows the receipt of certain third-party consents and the satisfaction of other closing conditions.
Biotech Intelligence (http://www.biotech-intelligence.com/html/html/2c33c729e97bf532879dbe640ba2d075.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May